Cochlear announces earnings upgrade
14 December, 2005 by Ruth BeranBionic ear specialist Cochlear (ASX:COH) has announced an upgrade of its guidance on core earnings for the 2005-06 financial year to AUD$80 million.
NZ-based VC invests in Cleveland Biosensors
14 December, 2005 by Helen SchullerBrisbane start-up Cleveland Biosensors has attracted investment capital from New Zealand-based VC BioPacific Ventures.
Alexanders Securities to strengthen biotech stake
14 December, 2005 by Ruth BeranAlexanders Securities (ASX:ALE), a financial services firm previously focused on investments in shares and providing venture capital to companies, is re-positioning itself as a consumer healthcare and biotechnology company.
Sunshine Heart raises $3.3m
13 December, 2005 by Helen SchullerSunshine Heart (ASX:SHC) has raised AUD$3.3 million through a private placement to fund the development of its C-Pulse heart assist device.
Biotech IPOs continue to test market
13 December, 2005 by Helen SchullerWhile many companies are preparing to shut down for the festive season, parts of the Australian biotech sector show no signs of getting into holiday mode.
CEO sees GTG leading the way for Aust biotech
13 December, 2005 by Graeme O'NeillA major court victory against US firm Applera will put Genetic Technologies (ASX:GTG) in a leadership position in Australian biotechnology, the firm's CEO has predicted.
Phylogica, McComb Foundation collaborate on burns treatment
09 December, 2005 by Ruth BeranPerth-based Phylogica (ASX:PYC) and the McComb Foundation are jointly developing a potential new drug to speed up the healing process and reduce the scarring caused by burns.
Premier Bionics raises $1.25m for Israeli trauma simulator
09 December, 2005 by Helen SchullerPremier Bionics (ASX:PBI) has raised AUD$1.25 million in a placement to provide capital to accelerate the development of a mass trauma simulator in Israel.
BTF earns fast growth kudos
09 December, 2005 by Helen SchullerPrivate Sydney-based biotech BTF has achieved 101 per cent revenue growth over the last three years, earning itself a place in the 2005 Deloitte Technology Fast 50 awards.
UNSW joins Uniseed fund, commits $10m
08 December, 2005 by Ruth BeranThe University of New South Wales (UNSW) has formally joined the pre-seed commercialisation fund Uniseed with a financial commitment of AUD$10 million.
Victoria-Israel R&D fund launched
07 December, 2005 by Ruth BeranA US$6 million fund was launched today for joint Israeli-Victorian projects in areas such as biotechnology, healthcare, nanotechnology, environmental technologies and advanced manufacturing.
New CEO at CogState
07 December, 2005 by Helen SchullerFollowing the resignation of CogState chief executive officer Peter Bick, Brad O'Connor has been promoted internally from chief financial officer to the CEO role.
No holiday for Regenera shareholders as firm re-jigs merger
07 December, 2005 by Helen SchullerShareholders in Regenera (ASX:RGA) have been asked to attend a meeting in Perth between Christmas and New Year, as the company seeks to revise terms of its planned merger with US firm Advanced Ocular Systems (AOS).
New Biota CEO speaks of road ahead
07 December, 2005 by Ruth BeranOn Friday, Biota Holdings (ASX:BTA) introduced Peter Cook as its new CEO and managing director, replacing Peter Molloy. On his first day at the company, Cook spoke with Ruth Beran about his background, the future for the company and the similarities between orbital engines and biotechnology.
Domantis, Bristol-Myers Squibb form partnership
06 December, 2005 by Graeme O'NeillUK firm Domantis, 36 per cent owned by Peptech (ASX:PTD), has signed an agreement with global pharma Bristol-Myers Squibb (NYSE:BMY) to develop domain-antibody (dAb) therapeutics for multiple immunology and cancer targets.
